tiprankstipranks
BridgeBio Pharma Inc (BBIO)
NASDAQ:BBIO

BridgeBio Pharma (BBIO) Stock News & Sentiment

849 Followers
BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
PremiumPress Releases
BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
6d ago
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
14d ago
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
PremiumPress Releases
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
18d ago
BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
PremiumPress Releases
BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
20d ago
BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024
PremiumPress Releases
BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024
21d ago
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
PremiumPress Releases
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
1M ago
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
1M ago
More BBIO News >

News Score - Last 7 Days

Neutral
BBIO
Sector Average
Media Buzz
This Week2 articles
Weekly Average4.5 articles
News Sentiment
This Week50%
Sector Average58%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is BBIO’s Media Buzz Sentiment?
2 articles about BBIO were published this week. In an average week, 4.5 articles are published.
    What is BBIO’s weekly average amount of articles?
    In an average week, 4.5 articles about BBIO are published.
      What is BBIO’s News Sentiment?
      50% of articles about BBIO were positive this week, compared to its sector average of 58%.
        Healthcare Stocks that are Trending in the News
        ALNYAlnylam Pharma
        SRPTSarepta Therapeutics
        ARGXArgenx Se
        ITCIIntra-Cellular Therapies
        DAWNDay One Biopharmaceuticals
        Showing the stocks with the most bullish news sentiment over the past week
        What's Included in PREMIUM?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis